Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Prospective, Multicenter, Phase II Clinical Study of First-line Treatment for HER2 (human Epidermal Growth Factor Receptor 2) Positive Advanced Gastric Cancer with Disitamab Vedotin in Combination with Tirelizumab and S-1

NCT05586061 is registered in ClinicalTrials.gov with Qilu Hospital of Shandong University as lead sponsor.

NCT NCT05586061
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05586061 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Prospective, Multicenter, Phase II Clinical Study of First-line Treatment for HER2 (human Epidermal Growth Factor Receptor 2) Positive Advanced Gastric Cancer with Disitamab Vedotin in Combination with Tirelizumab and S-1
Lead sponsor
Qilu Hospital of Shandong University
Phase
Phase 2
Overall status
Active, not recruiting
Start date
February 10, 2023
Completion date
December 31, 2025
Enrollment
55 (actual)
Sites
7

Conditions

As the registry lists them; a condition with its own page is linked.

her2-positive gastric cancer